Race is on for next-generation COPD drugs, but real payoff may be years away

Racing to get to market with new treatments for a common lung disease, drug developers may see an even more lucrative finish line further ahead.
First, however, drug developers are pushing new combinations of existing drugs or easier-to-use formulations.